Adam Brufsky, MD, PhD - Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice - a podcast by PVI, PeerView Institute for Medical Education
from 2020-10-30T18:00
Go online to PeerView.com/JTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts review the latest findings from randomized clinical trials as well as real-world studies assessing CDK 4/6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer, and discuss the complementary nature of clinical and real-world research and how data from both sources add to the body of evidence on this therapeutic class that helps inform clinical practice. Upon completion of this activity, participants should be better able to: Discuss real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in metastatic breast cancer, Establish best practices for analyzing and interpreting real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday oncology practice, Implement appropriate clinical decisions regarding the selection and use of CDK 4/6 inhibitors in the treatment of patients with metastatic breast cancer informed by the latest real-world and clinical trial evidence.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education